Related Experiment Videos
GSK-3beta directly phosphorylates and activates MARK2/PAR-1.
Shinichi Kosuga1, Etsu Tashiro, Toshifumi Kajioka
1Department of Bioscience and Informatics, Faculty of Science and Technology, Keio University, 3-14-1 Hiyoshi, Kohoku-ku, Yokohama 223-8522, Japan.
The Journal of Biological Chemistry
|November 1, 2005
Summary
Glycogen synthase kinase-3beta (GSK-3beta) activates MARK2, a kinase that phosphorylates tau protein at Ser-262. This GSK-3beta-MARK2 pathway is crucial for tau phosphorylation in Alzheimer disease (AD) pathogenesis.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Alzheimer disease (AD) is characterized by hyperphosphorylated tau protein aggregates.
- Serine-262 (Ser-262) is a major abnormal phosphorylation site on tau in AD brains.
- The activation mechanism of MicroRNA-262 (MARK2), a kinase targeting Ser-262, remains unclear.
Purpose of the Study:
- To investigate the role of glycogen synthase kinase-3beta (GSK-3beta) in the activation of MARK2.
- To elucidate the pathway responsible for tau phosphorylation at Ser-262 in Alzheimer disease.
Main Methods:
- Cell-based assays using lithium chloride (LiCl) to inhibit GSK-3beta.
- In vitro kinase assays with recombinant GSK-3beta and MARK2.
- Small interfering RNA (siRNA) mediated down-regulation of GSK-3beta and MARK2.
Main Results:
- GSK-3beta directly phosphorylates MARK2 at Ser-212, a site within its activation loop.
- Inhibition or down-regulation of GSK-3beta or MARK2 significantly reduced tau phosphorylation at Ser-262.
- GSK-3beta activates MARK2, which then phosphorylates tau at Ser-262.
Conclusions:
- Tau phosphorylation at Ser-262 in Alzheimer disease is primarily mediated by a pathway involving GSK-3beta activation of MARK2.
- This GSK-3beta-MARK2 pathway represents a potential therapeutic target for Alzheimer disease.